Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Combined Radiofrequency Ablation and Double Anti-Angiogenic Protein Therapy to Increase Coagulation Efficacy: An Experimental Study in a Murine Renal Carcinoma Model

  • Jun, Hong Young (Imaging Science Research Center, Wonkwang University School of Medicine) ;
  • Ryu, Jong-Hyun (Imaging Science Research Center, Wonkwang University School of Medicine) ;
  • Byun, Seung Jae (Department of Surgery, Wonkwang University School of Medicine) ;
  • Jeong, Chang Won (Imaging Science Research Center, Wonkwang University School of Medicine) ;
  • Kim, Tae-Hoon (Imaging Science Research Center, Wonkwang University School of Medicine) ;
  • Lee, Young Hwan (Department of Radiology, Wonkwang University School of Medicine) ;
  • Yoon, Kwon-Ha (Imaging Science Research Center, Wonkwang University School of Medicine)
  • Received : 2014.09.05
  • Accepted : 2015.03.18
  • Published : 2015.08.01
⟨ Previous Next ⟩

Abstract

Objective: To evaluate whether suppression of tumor microvasculature by double anti-angiogenic protein (DAAP) treatment could increase the extent of radiofrequency ablation (RFA)-induced coagulation in a murine renal cell carcinoma model. Materials and Methods: Renal cell carcinoma cell lines were implanted subcutaneously into 10 nude mice. Four mice received adenoviral DAAP treatment and 6 mice received sterile 0.9% saline solution as DAAP-untreated group. The effect of DAAP was evaluated according to the vascularity by contrast-enhanced ultrasound (CEUS) using microbubbles. Four DAAP-treated mice and 4 DAAP-untreated mice were then treated with RFA, resulting in 3 groups: no-therapy (n = 2), RFA only (n = 4), and RFA combined with DAAP treatment (n = 4). Immediately after RFA, the size of coagulation necrosis and mitochondrial enzyme activity were compared between the groups using analysis of variance (ANOVA) and post hoc test. Results: The contrast enhancement ratio for tumor vascularization on CEUS was significantly lower in the DAAP treated group than in DAAP-untreated group ($30.2{\pm}9.9%$ vs. $77.4{\pm}17.3%$; p = 0.021). After RFA, the mean coagulation diameter was 0 mm for no-therapy group, $6.7{\pm}0.7mm$ for the RFA only group and $8.5{\pm}0.4mm$ for the RFA with DAAP group (ANOVA, p < 0.001). The area of viable mitochondria within the tumor was $27.9{\pm}3.9%$ in no-therapy group, $10.3{\pm}4.5%$ in the RFA only group, and $2.1{\pm}0.7%$ in the RFA with DAAP group (ANOVA, p < 0.001). Conclusion: Our results suggest the potential value of combining RFA with anti-angiogenic therapy.

Keywords

References

  1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781 https://doi.org/10.1016/j.ejca.2009.12.014
  2. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398-406 https://doi.org/10.1016/j.eururo.2010.06.032
  3. Kim SY, Woo S, Hwang SI, Moon MH, Sung CK, Lee HJ, et al. Usefulness of resistive index on spectral Doppler ultrasonography in the detection of renal cell carcinoma in patients with end-stage renal disease. Ultrasonography 2014;33:136-142 https://doi.org/10.14366/usg.14001
  4. Tranquart F, Correas JM, Martegani A, Greppi B, Bokor D. [Feasability of real time contrast enhanced ultrasound in renal disease]. J Radiol 2004;85:31-36 https://doi.org/10.1016/S0221-0363(04)97542-7
  5. Choueiri TK, Schutz FA, Hevelone ND, Nguyen PL, Lipsitz SR, Williams SB, et al. Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology 2011;78:93-98 https://doi.org/10.1016/j.urology.2011.01.068
  6. Takaki H, Yamakado K, Soga N, Arima K, Nakatsuka A, Kashima M, et al. Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma. Jpn J Radiol 2010;28:460-468 https://doi.org/10.1007/s11604-010-0451-z
  7. Gervais DA. Cryoablation versus radiofrequency ablation for renal tumor ablation: time to reassess? J Vasc Interv Radiol 2013;24:1135-1138 https://doi.org/10.1016/j.jvir.2013.05.030
  8. Raman JD, Hall DW, Cadeddu JA. Renal ablative therapy: radiofrequency ablation and cryoablation. J Surg Oncol 2009;100:639-644 https://doi.org/10.1002/jso.21194
  9. Pirasteh A, Snyder L, Boncher N, Passalacqua M, Rosenblum D, Prologo JD. Cryoablation vs. radiofrequency ablation for small renal masses. Acad Radiol 2011;18:97-100 https://doi.org/10.1016/j.acra.2010.08.006
  10. Park S, Anderson JK, Matsumoto ED, Lotan Y, Josephs S, Cadeddu JA. Radiofrequency ablation of renal tumors: intermediate-term results. J Endourol 2006;20:569-573 https://doi.org/10.1089/end.2006.20.569
  11. Stern JM, Svatek R, Park S, Hermann M, Lotan Y, Sagalowsky AI, et al. Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours. BJU Int 2007;100:287-290 https://doi.org/10.1111/j.1464-410X.2007.06937.x
  12. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy. Cancer 2002;95:2353-2360 https://doi.org/10.1002/cncr.10966
  13. Shen P, Fleming S, Westcott C, Challa V. Laparoscopic radiofrequency ablation of the liver in proximity to major vasculature: effect of the Pringle maneuver. J Surg Oncol 2003;83:36-41 https://doi.org/10.1002/jso.10235
  14. Koh YJ, Kim HZ, Hwang SI, Lee JE, Oh N, Jung K, et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 2010;18:171-184 https://doi.org/10.1016/j.ccr.2010.07.001
  15. Jung K, Lee D, Lim HS, Lee SI, Kim YJ, Lee GM, et al. Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J Biol Chem 2011;286:14410-14418 https://doi.org/10.1074/jbc.M111.228130
  16. Ravaud A, Gross-Goupil M, Bellmunt J. Combination therapy in metastatic renal cell cancer. Semin Oncol 2013;40:472-481 https://doi.org/10.1053/j.seminoncol.2013.05.010
  17. Jun HY, Park SH, Kim HS, Yoon KH. Long residence time of ultrasound microbubbles targeted to integrin in murine tumor model. Acad Radiol 2010;17:54-60 https://doi.org/10.1016/j.acra.2009.07.017
  18. Zhang Q, Yang H, Kang SJ, Wang Y, Wang GD, Coulthard T, et al. In vivo high-frequency, contrast-enhanced ultrasonography of uveal melanoma in mice: imaging features and histopathologic correlations. Invest Ophthalmol Vis Sci 2011;52:2662-2668 https://doi.org/10.1167/iovs.10-6794
  19. Hwang M, Hariri G, Lyshchik A, Hallahan DE, Fleischer AC. Correlation of quantified contrast-enhanced sonography with in vivo tumor response. J Ultrasound Med 2010;29:597-607 https://doi.org/10.7863/jum.2010.29.4.597
  20. Shiyan L, Pintong H, Zongmin W, Fuguang H, Zhiqiang Z, Yan Y, et al. The relationship between enhanced intensity and microvessel density of gastric carcinoma using double contrast-enhanced ultrasonography. Ultrasound Med Biol 2009;35:1086-1091 https://doi.org/10.1016/j.ultrasmedbio.2009.03.010
  21. Horkan C, Ahmed M, Liu Z, Gazelle GS, Solazzo SA, Kruskal JB, et al. Radiofrequency ablation: effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model. J Vasc Interv Radiol 2004;15:269-274 https://doi.org/10.1097/01.RVI.0000109396.74740.C4
  22. Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, Goldberg SN. Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology 2006;240:82-89 https://doi.org/10.1148/radiol.2401050788
  23. Wang C, Yu C, Yang F, Yang G. Diagnostic accuracy of contrast-enhanced ultrasound for renal cell carcinoma: a meta-analysis. Tumour Biol 2014;35:6343-6350 https://doi.org/10.1007/s13277-014-1815-2
  24. Siracusano S, Quaia E, Bertolotto M, Ciciliato S, Tiberio A, Belgrano E. The application of ultrasound contrast agents in the characterization of renal tumors. World J Urol 2004;22:316-322 https://doi.org/10.1007/s00345-004-0410-3
  25. Williams R, Hudson JM, Lloyd BA, Sureshkumar AR, Lueck G, Milot L, et al. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. Radiology 2011;260:581-590 https://doi.org/10.1148/radiol.11101893
  26. Solbiati L, Ierace T, Tonolini M, Cova L. Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. Eur J Radiol 2004;51 Suppl:S19-S23 https://doi.org/10.1016/j.ejrad.2004.03.035
  27. Liu JB, Goldberg BB, Merton DA, Rawool NM, Needleman L, Forsberg F. The role of contrast-enhanced sonography for radiofrequency ablation of liver tumors. J Ultrasound Med 2001;20:517-523 https://doi.org/10.7863/jum.2001.20.5.517
  28. Hines-Peralta A, Goldberg SN. Review of radiofrequency ablation for renal cell carcinoma. Clin Cancer Res 2004;10(18 Pt 2):6328S-6334S https://doi.org/10.1158/1078-0432.CCR-050004
  29. Hakime A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, et al. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology 2007;244:464-470 https://doi.org/10.1148/radiol.2442061005

Cited by

  1. Safety and effectiveness of percutaneous radiofrequency ablation in early stage renal cell carcinoma vol.12, pp.6, 2016, https://doi.org/10.3892/ol.2016.5267
  2. Percutaneous Dual-Switching Monopolar Radiofrequency Ablation Using a Separable Clustered Electrode: A Preliminary Study vol.18, pp.5, 2015, https://doi.org/10.3348/kjr.2017.18.5.799
  3. Basic Knowledge in Soft Tissue Sarcoma vol.42, pp.9, 2015, https://doi.org/10.1007/s00270-019-02259-w
  4. Combined microwave ablation and antiangiogenic therapy to increase local efficacy vol.29, pp.2, 2015, https://doi.org/10.1080/13645706.2019.1601632